Medicinal cannabis
November 21, 2023
The prescribing and supply of medicinal cannabis is a rapidly expanding area of practice in Australia. With this emerging field comes the need for comprehensive
The prescribing and supply of medicinal cannabis is a rapidly expanding area of practice in Australia. With this emerging field comes the need for comprehensive
Off-label prescribing occurs when a medication is used for a purpose that is not approved by the Australian Therapeutic Goods Administration (TGA). It may involve
In recent weeks, the PDL Professional Officers have received a number of queries regarding pharmacists’ obligations and liability when dispensing Mounjaro® (tirzepatide). Tirzepatide is a
Pharmacists have limited time left to register their interest in their pharmacy taking part in the NSW Pharmacy Trial, with the expression of interest process
The PDL Professional Officers often manage calls, incident reports and occasional regulatory complaints following a pharmacist’s decision to decline supply of a medication. Recently, the
PDL is raising awareness with hospital pharmacists about the need to report incidents to PDL. This call has been prompted by a recent review of
Victorian pharmacists may be aware of the Community Pharmacist Statewide Pilot scheduled to go live towards the end of October. PDL continues to support the
The NSW Government-sponsored Pharmacy Trial for the extended supply of oral contraceptive pills (OCPs) by community pharmacists commenced on 27 September 2023. The trial aims
Pharmacists are at the forefront of patient care, ensuring the safe and effective use of medications. Despite pharmacists best efforts, incidents can result in complaints,
On 13 September 2023, the WA Government released a new Structured Administration and Supply Arrangement (SASA) that authorises a registered pharmacist trained in the Community Program